Form 4: Stoke Therapeutics Director Receives Stock Option Grant

Director Arthur Tzianabos was granted 17,786 stock options in Stoke Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Arthur Tzianabos received a grant of 17,786 stock options on June 3, 2026.
• The options have an exercise price of $29.46 per share.
• The options are set to expire on June 2, 2036.
• The grant vests in full on the earlier of June 3, 2027, or the date of the next annual stockholder meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution for existing shareholders upon exercise of the options.

Risks

• Vesting is contingent upon the director's continued service to the issuer.

Future Outlook

The options vest in one year, aligning the director's tenure with the company's upcoming annual meeting cycle.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard corporate governance practices for mid-cap biotechnology firms.
• The use of time-based vesting is a common industry benchmark for director compensation.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 3, 2027, or the next annual meeting.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Stock Options, Equity Compensation